Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Including Subjects Undergoing Hemodialysis: A Phase 2, Open-label, Multicenter Trial

NCT02977494 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT02977494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02977494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Including Subjects Undergoing Hemodialysis: A Phase 2, Open-label, Multicenter Trial
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
June 30, 2021
Enrollment
22 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma